CN108785388A - A kind of composite formula and preparation method treating and preventing diabetes and its complication - Google Patents
A kind of composite formula and preparation method treating and preventing diabetes and its complication Download PDFInfo
- Publication number
- CN108785388A CN108785388A CN201710280770.XA CN201710280770A CN108785388A CN 108785388 A CN108785388 A CN 108785388A CN 201710280770 A CN201710280770 A CN 201710280770A CN 108785388 A CN108785388 A CN 108785388A
- Authority
- CN
- China
- Prior art keywords
- diabetes
- composite formula
- complication
- extract
- mulberry
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 39
- 239000002131 composite material Substances 0.000 title claims abstract description 19
- 238000002360 preparation method Methods 0.000 title abstract description 8
- 238000009472 formulation Methods 0.000 title description 3
- 239000003814 drug Substances 0.000 claims abstract description 20
- 235000000346 sugar Nutrition 0.000 claims abstract description 17
- 239000000463 material Substances 0.000 claims abstract description 15
- 229940079593 drug Drugs 0.000 claims abstract description 13
- 208000002249 Diabetes Complications Diseases 0.000 claims abstract description 11
- 206010012655 Diabetic complications Diseases 0.000 claims abstract description 9
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 8
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 7
- 239000011358 absorbing material Substances 0.000 claims abstract description 4
- 230000000903 blocking effect Effects 0.000 claims abstract description 4
- AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 claims description 28
- 239000000284 extract Substances 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 18
- 235000019136 lipoic acid Nutrition 0.000 claims description 16
- 229960002663 thioctic acid Drugs 0.000 claims description 16
- 230000000694 effects Effects 0.000 claims description 13
- 235000013305 food Nutrition 0.000 claims description 11
- 235000021388 linseed oil Nutrition 0.000 claims description 10
- 239000000944 linseed oil Substances 0.000 claims description 10
- 229960002873 benfotiamine Drugs 0.000 claims description 9
- BTNNPSLJPBRMLZ-LGMDPLHJSA-N benfotiamine Chemical compound C=1C=CC=CC=1C(=O)SC(/CCOP(O)(O)=O)=C(/C)N(C=O)CC1=CN=C(C)N=C1N BTNNPSLJPBRMLZ-LGMDPLHJSA-N 0.000 claims description 9
- 206010022489 Insulin Resistance Diseases 0.000 claims description 7
- 235000006708 antioxidants Nutrition 0.000 claims description 7
- -1 isobutyl sulphur Amine Chemical class 0.000 claims description 7
- 229960003495 thiamine Drugs 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 claims description 6
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 claims description 5
- 229930003451 Vitamin B1 Natural products 0.000 claims description 5
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 5
- 235000020717 hawthorn extract Nutrition 0.000 claims description 5
- BJHIKXHVCXFQLS-PQLUHFTBSA-N keto-D-tagatose Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-PQLUHFTBSA-N 0.000 claims description 5
- 235000010374 vitamin B1 Nutrition 0.000 claims description 5
- 239000011691 vitamin B1 Substances 0.000 claims description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- 230000036541 health Effects 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 claims description 3
- 230000005764 inhibitory process Effects 0.000 claims description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 2
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims description 2
- 229930003268 Vitamin C Natural products 0.000 claims description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims description 2
- 235000019157 thiamine Nutrition 0.000 claims description 2
- 239000011721 thiamine Substances 0.000 claims description 2
- 235000019154 vitamin C Nutrition 0.000 claims description 2
- 239000011718 vitamin C Substances 0.000 claims description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 2
- 241000241413 Propolis Species 0.000 claims 2
- 239000006187 pill Substances 0.000 claims 2
- 229940069949 propolis Drugs 0.000 claims 2
- WNCAVNGLACHSRZ-KAMYIIQDSA-N Allithiamine Chemical compound C=CCSSC(/CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N WNCAVNGLACHSRZ-KAMYIIQDSA-N 0.000 claims 1
- WNCAVNGLACHSRZ-UHFFFAOYSA-N Allithiamine Natural products C=CCSSC(CCO)=C(C)N(C=O)CC1=CN=C(C)N=C1N WNCAVNGLACHSRZ-UHFFFAOYSA-N 0.000 claims 1
- 239000009636 Huang Qi Substances 0.000 claims 1
- 244000302512 Momordica charantia Species 0.000 claims 1
- 235000009811 Momordica charantia Nutrition 0.000 claims 1
- 235000009812 Momordica cochinchinensis Nutrition 0.000 claims 1
- 235000018365 Momordica dioica Nutrition 0.000 claims 1
- 240000004980 Rheum officinale Species 0.000 claims 1
- 235000008081 Rheum officinale Nutrition 0.000 claims 1
- 229930003427 Vitamin E Natural products 0.000 claims 1
- 235000009754 Vitis X bourquina Nutrition 0.000 claims 1
- 235000012333 Vitis X labruscana Nutrition 0.000 claims 1
- 240000006365 Vitis vinifera Species 0.000 claims 1
- 235000014787 Vitis vinifera Nutrition 0.000 claims 1
- 229940107666 astragalus root Drugs 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 229940046009 vitamin E Drugs 0.000 claims 1
- 235000019165 vitamin E Nutrition 0.000 claims 1
- 239000011709 vitamin E Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 19
- 239000008280 blood Substances 0.000 abstract description 19
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 16
- 239000008103 glucose Substances 0.000 abstract description 16
- 238000000034 method Methods 0.000 abstract description 12
- 238000011161 development Methods 0.000 abstract description 6
- 230000002265 prevention Effects 0.000 abstract description 6
- 230000003285 pharmacodynamic effect Effects 0.000 abstract description 5
- 230000007246 mechanism Effects 0.000 abstract description 3
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 206010018429 Glucose tolerance impaired Diseases 0.000 abstract 1
- 208000001280 Prediabetic State Diseases 0.000 abstract 1
- 201000009104 prediabetes syndrome Diseases 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 238000012545 processing Methods 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- 238000000855 fermentation Methods 0.000 description 6
- 230000004151 fermentation Effects 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 238000000465 moulding Methods 0.000 description 5
- 230000007830 nerve conduction Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 5
- 108010005094 Advanced Glycation End Products Proteins 0.000 description 4
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 235000013312 flour Nutrition 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 230000001953 sensory effect Effects 0.000 description 4
- 239000007901 soft capsule Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 240000000249 Morus alba Species 0.000 description 3
- 235000008708 Morus alba Nutrition 0.000 description 3
- 102100023347 Proto-oncogene tyrosine-protein kinase ROS Human genes 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 229930013930 alkaloid Natural products 0.000 description 3
- 150000003797 alkaloid derivatives Chemical class 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 210000004126 nerve fiber Anatomy 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 230000007863 steatosis Effects 0.000 description 3
- 231100000240 steatosis hepatitis Toxicity 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 235000013618 yogurt Nutrition 0.000 description 3
- GIANIJCPTPUNBA-QMMMGPOBSA-N (2s)-3-(4-hydroxyphenyl)-2-nitramidopropanoic acid Chemical compound [O-][N+](=O)N[C@H](C(=O)O)CC1=CC=C(O)C=C1 GIANIJCPTPUNBA-QMMMGPOBSA-N 0.000 description 2
- RSWGJHLUYNHPMX-UHFFFAOYSA-N 1,4a-dimethyl-7-propan-2-yl-2,3,4,4b,5,6,10,10a-octahydrophenanthrene-1-carboxylic acid Chemical compound C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000058061 Glucose Transporter Type 4 Human genes 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010018473 Glycosuria Diseases 0.000 description 2
- 206010029164 Nephrotic syndrome Diseases 0.000 description 2
- 208000017442 Retinal disease Diseases 0.000 description 2
- 206010038923 Retinopathy Diseases 0.000 description 2
- 108091006300 SLC2A4 Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 230000036982 action potential Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 2
- 230000003178 anti-diabetic effect Effects 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 235000008429 bread Nutrition 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000000763 evoking effect Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 210000002239 ischium bone Anatomy 0.000 description 2
- 229960004488 linolenic acid Drugs 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 235000013310 margarine Nutrition 0.000 description 2
- 239000003264 margarine Substances 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000003068 molecular probe Substances 0.000 description 2
- 208000009928 nephrosis Diseases 0.000 description 2
- 231100001027 nephrosis Toxicity 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 210000003497 sciatic nerve Anatomy 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 229910001369 Brass Inorganic materials 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- LXJXRIRHZLFYRP-VKHMYHEASA-N D-glyceraldehyde 3-phosphate Chemical compound O=C[C@H](O)COP(O)(O)=O LXJXRIRHZLFYRP-VKHMYHEASA-N 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 241000907681 Morpho Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 229920000388 Polyphosphate Polymers 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 102000014701 Transketolase Human genes 0.000 description 1
- 108010043652 Transketolase Proteins 0.000 description 1
- 102100025038 Ubiquitin carboxyl-terminal hydrolase isozyme L1 Human genes 0.000 description 1
- 101710186825 Ubiquitin carboxyl-terminal hydrolase isozyme L1 Proteins 0.000 description 1
- 241000256856 Vespidae Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 230000002058 anti-hyperglycaemic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000010951 brass Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000000078 claw Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000001218 confocal laser scanning microscopy Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 201000002342 diabetic polyneuropathy Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 238000005562 fading Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229930182486 flavonoid glycoside Natural products 0.000 description 1
- 150000007955 flavonoid glycosides Chemical class 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 235000021552 granulated sugar Nutrition 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 239000008236 heating water Substances 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000012308 immunohistochemistry method Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 238000005470 impregnation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000011542 limb amputation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000003754 machining Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 238000010197 meta-analysis Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000005404 monopole Effects 0.000 description 1
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000012014 optical coherence tomography Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 150000002972 pentoses Chemical class 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 239000001205 polyphosphate Substances 0.000 description 1
- 235000011176 polyphosphates Nutrition 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 235000020201 recombined milk Nutrition 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000000453 second toe Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000009923 sugaring Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 229940035936 ubiquinone Drugs 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/55—Linaceae (Flax family), e.g. Linum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to it is a kind of for treat and prevent diabetes and diabetic complication composite formula, and its preparation method and application method, be made of following component：Inhibit sugar absorbing material, antioxidant, diabetic complication blocking drugs, and the pharmaceutically acceptable auxiliary material present invention is using the key node in onset diabetes mechanism as target position, the different parts of different phase during selecting different acting factors to attack diabetes occurrence and development, reach the synergistic effect of pharmacodynamics, prevention to diabetes, block the development of pre-diabetes, control blood glucose level and prevent diabetes complication it is all helpful, and then diabetes community is helped to make the life better quality.
Description
Technical field
The invention belongs to pharmaceutical technology fields, are related to a kind of pharmaceutical composition, and in particular to a kind for the treatment of and prevention glycosuria
The pharmaceutical composition of disease and its complication, while present composition formula is also applied for field of health care food.
Background technology
Type-2 diabetes mellitus (DM) is quickly becoming most common chronic disease, has affected the adult population in the whole world 7%.
Just develop with surprising rapidity, World Health Organization the main reason for high income countries population is dead in being included in it
One.It is just resisting with this disease in fact, having had more than 30,000,000 people in Canada and the U.S. at present, however every year still
There are 1,500,000 new cases to be diagnosed, does not include about one third also here and suffer to the impacted people of half because not knowing oneself
It is sick and not diagnosed.Although these numbers seem very surprising, it is contemplated that these data in following 10 years
50% is will increase more than, diabetes overflow at last.
The characteristics of diabetic is the metabolic disorder along with elevated blood glucose levels all the life, over time, may
It can cause such as heart disease, blindness, kidney failure and neurotrosis complication.In addition, diabetes and weight gain also have directly
Contact.The increase of the food intake and sitting behavior of high-energy, resulting in modern humans becomes increasingly fatter, thus causes
The increase of insulin resistant, insulin resistant the result is that increase aliphatic acid flow out into artery from adipocyte (FFA)
Endothelial cell.It is this to increase the oxidation increase for resulting in adipocyte mitochondrial in the endothelial cell of big blood vessel, to lead
Cause the excess production capacity of active oxygen (ROS) and along with the Pathway Activation for causing diabetic complication, such as advanced glycosylation end product
(AGE) access, protein kinase (CPKC) access, hexose amine access, the activation of nuclear factor (NF κ B) access, once these are logical
Road is active, will cause blood vessel pathological change, the sensibility raising of inflammatory factor and growth factor, and comprehensive gene table
The pathological change reached.These serious consequences not only significantly reduce the quality of life of a people, but also serious affect
The economic development of country.In the U.S., be respectively with diabetes relevant medical expense estimation directly or indirectly 91,800,000,000 dollars and
39800000000 dollars, account for the 6.6% of total medical expense.
Control blood glucose level appropriate is the key that prevent diabetes and its complication.Blood glucose level is reduced, can help to
Alleviate the complication caused by diabetes, such as myocardial infarction, apoplexy, lower limb amputation, microvascular disease and cataract etc..It forms
Good life style controls blood glucose level, including increases physical training and reduction
In recent years, the drug of a large amount of natural and synthesis anti-diabetic emerges.But the effect of these drugs
It is limited, is mainly shown as that they are unable to control the reduction of postprandial hyperglycemia, main cause has：1, these drugs are to pancreas
The inhibition that glucagons and hepatic glucose generate is insufficient；2, gastric emptying can not be reduced；3, satiety and feeling of repletion can not be improved；4,
Improperly glucose periphery is removed；5, promote hypoinsulinism.For these reasons, the safer and more effective anti-glycosuria of screening
Sick product is still a very important research field.
Based on the pathological cause of above-mentioned diabetes, we devise for the different target position in onset diabetes mechanism,
In conjunction with the medicine for reducing antihyperglycemic drug, anti-oxidation preparation, promotion insulin sensitivity drug and blocking diabetic complication access
Object provides the pharmaceutical composition of a kind of safer and more effective treatment and prevention diabetes and its complication, for substituting or
The traditional antidiabetic medicine of auxiliary, helps patient to reach the blood glucose level of health, while patient being helped to prevent and improve diabetes
The symptom of complication.
Invention content
The purpose of the present invention is to provide a kind of novel composite formula, be mainly used for treating and preventing diabetes and
The characteristics of neuropathy caused by diabetes, nephrosis and retinopathy, the composition, is：Peomote sugared generation
It thanks, postprandial blood sugar is inhibited to increase and enhance the effect of insulin sensitivity.
To achieve the above object, the present invention adopts the following technical scheme that：
A kind of composite formula treating and preventing diabetes and its complication of the present invention, consists of the following compositions：Suppression
Sugaring divides absorbing material, antioxidant to block the substance of diabetic complication access and pharmaceutically acceptable auxiliary material.
Preferred composite formula is mulberry-leaf extract, alpha-lipoic acid, benfotiamine, linseed oil.
According to the prior art it is found that the safely and effectively dosage model that each component in present composition formula is used alone
It encloses as described below respectively：Mulberry-leaf extract 0.8-3.0g (bibliography Zhong, Litao, Julie K.Furne, and
Michael D.Levitt. " An extract of black, green, and mulberry teas causes
malabsorption of carbohydrate but not of triacylglycerol in healthy
volunteers.″The American journal of clinical nutrition 84.3 (2006)：551-555.)；
Alpha-lipoic acid 600mg (bibliography Ziegler, D., et al. " Treatment of symptomatic diabetic
polyneuropathy with the antioxidant α-lipoic acid：a meta-analysis.″Diabetic
Medicine 21.2(2004)：114-121.Saeid Golbidi, Ismail Laher 2010)；Benfotiamine 40-
250mg (bibliography Beltramo, Elena, et al. " Effects of thiamine and benfotiamine on
intracellular glucose metabolism and relevance in the prevention of diabetic
complications.″Acta diabetologica 45.3(2008)：131.)；(bibliography is linseed oil 2-28g
Delarue, Jacques, et al. " N-3long chain polyunsaturated fatty acids：a
nutritional tool to prevent insulin resistance associated to type 2 diabetes
and obesity.″Reproduction Nutrition Development 44.3(2004)：289-299.)
Preferred composition and its quality proportioning are：Mulberry-leaf extract 80-100mg, alpha-lipoic acid 100-150mg, benzene phosphorus
Sulphur ammonium 40-60mg and linseed oil 300-400mg.Most preferred combination is：Mulberry-leaf extract 100mg, alpha-lipoic acid
150mg, benfotiamine 50mg and linseed oil 300mg.
The extracting method of mulberry-leaf extract of the present invention is multiple water extraction.
Compared with prior art, beneficial effects of the present invention：Morbidity machine of the invention formula based on diabetes and its complication
Reason in conjunction with control hypoglycemic medicament, anti-oxidation medicine, promotes insulin sensitivity drug and diabetic complication blocking drugs, carries
A kind of drug that can control blood glucose level in patients is supplied, at the same time, it may also help in prevention and improves diabetes complicated
The symptom of disease.Selected mulberry-leaf extract, which has, in composition of medicine of the present invention inhibits blood glucose rise after meal, reduces blood glucose fluctuation
The effect of, control blood glucose level is played in diabetes access, reduces the generation of active oxygen (ROS)；Alpha-lipoic acid is a kind of non-
The coenzyme of normal important citrate cycle, citrate cycle is the carbohydrate-modifying main process for the energy of body.α-
Lipoic acid or a kind of very powerful antioxidant, he can remove hydroxyl radical free radical, singlet oxygen and hypochlorous acid, while it
Removing heavy metals, and direct or indirect regeneration such as glutathione, vitamin C, dimension life can also be gone by way of chelating
The antioxidants such as plain E, ubiquinone (Co-Q10).This inoxidizability ability can inhibit in diabetes and its complication access
ROS activity, to inhibit the development of diabetes and its complication, in addition, alpha-lipoic acid is it is verified that can be used for raising two
Sensibility of the diabetes mellitus type to insulin；Benfotiamine can activate transketolase, and superfluous triose phosphate is made to enter phosphorus
Sour pentose metabolism approach, to prevent the formation (AGE) of advanced glycosylation end product and alleviate the pressure of cell metabolism；It is sub-
Flaxseed oil is the solvent of benfotiamine and alpha-lipoic acid, and the main component of itself is alpha-linolenic acid, and alpha-linolenic acid has and prevents
The consumption of glucose transporter GLUT4 in the active reduction of phosphatidylinositol3 3 kinase (PI3 kinases) and muscle；, also have pre-
GLUT4 expression reduces in anti-adipose tissue, so linseed oil is also helpful to the treatment of diabetes.Above-mentioned four kinds of drugs point
Pharmacodynamics mechanism that Ju You be not different acts on the different pathological physiological stage of diabetes, and again with collaboration between each component
The function of synergy, the experiment proved that (detailed in Example 2), the composition of four kinds of ingredients imitates the treatment of diabetes and its complication
Fruit will be significantly better than the independent effect of each component.Therefore, inventive formulation has effects that following and is better than its one-component, suppression
System blood glucose rise after meal increases insulin sensitivity, reduces insulin resistance, sanatory glycometabolism, prevention and improve
Neuropathy caused by being increased by blood sugar concentration, nephrosis, retinopathy.
Description of the drawings：
Fig. 1 is mulberry-leaf extract preparation flow figure；
Fig. 2 is that composition is used for yogurt production processing process figure；
Fig. 3 is composition for the breadmaking processing process figure that ferments
Specific implementation mode
The preparation method of 1 mulberry-leaf extract of embodiment
It is known in the prior art that the main active substances for treating diabetes in mulberry leaf are alkaloid, polysaccharide and flavonoid glycoside.
These types of active material has preferable water solubility, so can not only effectively propose active constituent by solvent extraction of water, and
In production and use, that is, safe and cost-effective.
The assay method of alkaloid is not very ripe, and application condition is big, and the activity of brass class compound is than alkaloid and more
Sugar is low, and polysaccharide not only content highest in extract, is main active constituent, and detection method is relatively simple, therefore this
The quality control index of mulberry-leaf extract is selected as polyoses content in invention, and the polyoses content detection method used is the dense sulphur of anthrone-
Sour development process.
Mulberry-leaf extract preparation method：30kg mulberry leaf cuttings are taken, are placed in 500L extractors, 300L deionized waters are added,
Steam is passed through to 80 DEG C, keeps the temperature 2 hours, with diatomaceous earth filter filter and remove suspended substances, repeats extraction 1 time, merging filtrate subtracts
Pressure boils off solvent, is dried in vacuo, hygroscopicity brown product is obtained after crushing.The rate of recovery is should be more between 13.0%-14.0%
Sugared content should be between 31.0%-32%.Process flow chart is as shown in Figure of description 1.
Implement 2 present composition of side to test type-2 diabetes mellitus therapeutic effect
According to FDA test directions (Guidance, F.D.A. " Estimating the maximum safe starting
dose in initial clinical trials for therapeutics in adult healthy
Volunteers. " Rockville, MD, USA (2005)), human body pharmacodynamics test dosage turns with pharmacodynamics in Mice test dose
It is 12.3 to change parameter, i.e. people's dosage × 12.3=mouse doses, according to this field Normal practice, the conversion dosage generally as
Median dose can upwardly or downwardly adjust 2-3 times of relationship on this basis, and high dose or low dosage is arranged.Accordingly,
The pharmacodynamics in Mice test dose used in the present invention is as follows：
Following tests selects C57B16/J mouse, and in addition to the reagent of specified otherwise, remaining is purchased from Sigma Aldrich
Chemical Co., not specified specific test procedure and parameter are carried out according to this field Normal practice.
Test mice is divided into 7 groups, and every group 8, the specific situation that is grouped see the table below.The mouse diet of 1-8 week old, the 8th
In week, remaining 6 groups of carry out nursing high in fat, for 4 weeks in addition to Normal group, and nursing specific embodiment high in fat is：
The food of 60 kilocalories of the daily feeding of mouse, does not control drinking-water, in first day intraperitoneal injection streptozotocin 75mg/ of high-fat fed
Kg detects its cavity blood glucose after 3 days, such as blood glucose value >=13.8mmol/L (250mg/dl), then it is assumed that mouse is successfully configured to II
Patients with type Ⅰ DM model can inject a needle 50mg/kg streptozotocins in third day dosage if needed.Start according to following table within 12nd week
It is grouped situation and carries out Intervention trial, continue 12 weeks.
The following index of mouse is detected after 24 weeks：Weight, fasting plasma glucose concentration, serum lipid concentrations (triglycerides, free resin acid,
Cholesterol), liver nitrotyrosine is horizontal, steatosis area, movement and sensory nerve conduction velocity, when the reaction of hot pain
Between, LI nerve fibers in epidermis.Test is carried out with mono blind method as far as possible.
Wherein, blood sugar concentration and blood lipid level are tested using related kit, other experiments are as described below：
Hot pain reaction time test：
Experiment terminates the previous day, and hind leg hot pain is measured using Hargreaves method (Hargreaves method)
Reaction, instrument use IITC Life Science；Woodland Hills, CA (model 390G) or UARD (San
Diego).Mouse is placed on to the top for the heat examination experiment device for observing and measuring room, and its adaptive temperature is allowed to be 30 DEG C of glass surface
15 minutes.Heat source is placed under mouse hind leg heel, timer is then turned on, while heating up to glass surface, works as mouse
Claw is recalled, closes heat source and timing, time of day is the second.Duplicate measurements four times is rested about 5 minutes between every group of measurement.It surveys
Mean value is calculated after amount, is used as weighing the response delay of hot pain.
Movement and sensory nerve conduction velocity experiment：
The yellow Jackets that 75mg/kg is injected to mouse peritoneal are anaesthetized.Then movement and sensory nerve conduction are measured
Speed.Briefly, it is exactly the ischium shin bone conducting system that Noninvasive is used in the environment of controlled temperature.First in ischium
Incision stimulates left sciatic nerve, and left sciatic nerve is then stimulated at heel string.Stimulus is to be passed through 0.2ms super larges (8V) simple venation
Bipolar electrode (the Grass S44 stimulators of punching；Grass Medical Instruments, Quincy, MA).Interosseus meat
Evoked ptential records (model 54600A with monopole platinum electrode；Hewlett-Packard, Rolling Meadows, IL).Movement
The ratio table of the distance (unit mm) and transmission time (unit ms) of nerve conduction velocity Evoked ptential initiating terminal to clearing end
Show.It by using the minimum strength electric current that amplitude peak responds, is stimulated with the square-wave pulse of 0.05ms, records the second toe and interior
The action potential of ankle.By the ratio for measuring the stand-by period and the distance between action potential of starting/peak value of original negative deflection
Value calculates sensory nerve conduction velocity.
LI nerve fibers are tested in epidermis：
Use LI nerve fibers in ImmunohistochemistryMethods Methods detection epidermis.The skin of fixed right rear solid end, paraffin embedding, slice
7mm carries out immunostaining (AbD Serotic, Morpho Sys US Inc., Raleigh), altogether with rabbit-anti people's PGP9.5 antibody
Focusing microscope is observed.
Steatosis areal analysis：
In order to check steatosis, by liver sample as liquid nitrogen frozen in optical coherence tomography compound.By liver
Be sliced (5 μm) and BODIPY molecular probes (Carlsbad, CA) in 1% bovine serum albumin(BSA) with 1: 5000 ratio in room temperature
It is lower to incubate 1 hour.After washing, useThe anti-color fading reagents of Gold (Molecular Probes, Carlsbad, CA)
Liver slice is loaded, is used in combination 710 LSM confocal laser scanning microscopies of Zeiss to collect image, uses Image J software analysis figures
The area fraction percentage of the fat drips of picture.
Test result see the table below：
Note：Data are expressed as average value ± SD.* the P < 0.05 compared with control mice；The P < compared with diabetic mice
0.05.
As can be seen from the above table, after 12 weeks therapeutic interventions, the blood sugar concentration of composition intervention group and every blood
Lipid level (triglycerides, free resin acid, cholesterol, liver nitrotyrosine) will be significantly lower than untreated diabetes group and other
Every one-component test group, this shows that the present composition can prevent and treat diabetes-associated symptoms, while curative effect wants excellent
In one-component.In addition, the present composition can entirely prevent fatty variation, and to the relevant peripheral neuropathic of multiple diabetes
Lesion all makes moderate progress, and the therapeutic effect of composition is compared with one-component medication effect, hence it is evident that more effect.This shows
The pharmaceutical composition of the present invention, which not only has, treats and prevents diabetes-associated symptoms, while also having and treating and preventing by diabetes
The effect of caused various complication, and there is synergistic effect, combination between present composition each component it can be seen from experiment
The therapeutic effect of object will be substantially better than the therapeutic effect of one-component.
It is prepared by embodiment 3-11 pharmaceutical compositions
Benfotiamine is dissolved in a small amount of linseed oil, is then added in whole linseed oil, keeps room temperature.By material proportion
(see the table below) slowly mixes mild oil plant with alpha-lipoic acid, and stirs 2 hours, and until soluble fraction is dissolved in oil, it is added
Its raw material is uniformly mixed.It is milled to feel exquisiteness by colloid mill, then is less than 0.5 μm with homogenizer homogeneous to particle, after the completion
Material is poured into vacuum stirring degasser, vacuum is transferred to -0.09mpa, without heating, stirring degassing 2-3 hours.Material
It is spare.
Impregnation：Gelatin, glycerine, deionized water in 1: 0.4-0.6: 1 ratio be added glue-mixing tube in, heating water bath to 60 DEG C-
65 DEG C, vacuum -0.05mPa to -0.09mPa is stirred 3-4 hours, is released in gelatin solution to insulation barrel and is kept the temperature 6-8 hours, spare.
Pelleting, drying and moulding：With soft capsule pellet processing machine, by the gelatin of preparation and materiel machining at prescribed dose, shape
Capsule, and it is input to rotating cage drying machine, environment temperature is 15-20 DEG C, and relative humidity is RH 40%-50%, is rotated 2-3 hours.
Ball is washed, it is dry, ball is picked, is packed：It is cleaned and dried molding capsule with 95% ethyl alcohol, removes the dirty stain on surface, it will
Soft capsule after washing is put into rotating cage, and environment temperature at this time is 26 DEG C ± 2 DEG C, relative humidity 30%-40%, drying about 5
Hour, after completing this process, sort out shape unsightly, has bubble, problematic soft capsule ball, qualified soft capsule to be packaged into
For finished product.
Specific material proportion see the table below, and following table is the material proportion of each capsule 's content, and daily four capsules of people are raw
Mass conversion is carried out according to specific output during production.
| Linseed oil/mg | Alpha-lipoic acid/mg | Benfotiamine/mg | Mulberry-leaf extract/mg | |
| Embodiment 3 | 300 | 100 | 40 | 80 |
| Embodiment 4 | 300 | 125 | 50 | 90 |
| Embodiment 5 | 300 | 150 | 60 | 100 |
| Embodiment 6 | 350 | 100 | 50 | 100 |
| Embodiment 7 | 350 | 125 | 60 | 80 |
| Embodiment 8 | 350 | 150 | 40 | 90 |
| Embodiment 9 | 400 | 100 | 60 | 90 |
| Embodiment 10 | 400 | 125 | 40 | 100 |
| Embodiment 11 | 400 | 150 | 50 | 80 |
The food processing high for sugar content of 12 composite formula of embodiment
The composite formula used in the present embodiment be L-arabinose, haw thorn extract and vitamin B1, recommendation it is every
Daily intake is the 3-4% that L-arabinose is sugar in food, and haw thorn extract is 450-550mg/ days, and vitamin B1 is
25-35mg/ days, preferred material proportion was 3.5% that L-arabinose is sugar in food, haw thorn extract 500mg/
It, vitamin B1 is 30mg/ days.Below by taking the making of Yoghourt as an example, but the formula is not limited to Yoghourt, which can be additionally used in
Soda, fruit juice, the higher food of ice cream and milk beverage etc. sugar content.
Material proportion：
| Material | Ratio/% | Material | Ratio/% |
| Milk powder recombined milk | 89 | Fruit milk emulsion stabilizer | 0.4 |
| Leavening | 4 | L-arabinose | 0.21 |
| Essence | 0.1 | Haw thorn extract | 0.25 |
| White granulated sugar | 6 | Vitamin B1 | 0.03 |
| Protein sugar | 0.06 | Polyphosphate sodium | 0.05 |
| Sodium citrate | 0.05 |
Fabrication processing figure refers to Figure of description 2.
Main technologic parameters：
(1) raw material mixture temperature：50~60 DEG C；
(2) sterilization conditions：85 DEG C, 25 minutes；
(3) processing condition：60 DEG C, 15~18Mpa；
(4) cooling condition：40~42 DEG C；
(5) fermentation condition：40~42 DEG C；
(6) canned volume：200g.
13 composite formula of embodiment is for sugar content to be low or the processing of sugarfree foods
The composite formula used in the present embodiment is Tagatose, Bitter Melon P.E and arasaponin, wherein for low sugar
Food, Tagatose can be added directly into instead of sucrose in food, and for sugarfree foods, the additive amount of Tagatose is in 0-2.0%
Between, the additive amount of Bitter Melon P.E is 1.0%-2.0%, and arasaponin additive amount is 3%-4%.The present embodiment is with the face of fermenting
For packet.
Material proportion：
| Material | Ratio/% | Material | Ratio/% |
| Tailored flour for bread | 57% | Milk powder | 1 |
| Send out active dry yeast | 0.7 | Water | 32-35% |
| Salt | 0.9 | Margarine | 1.5 |
| Tagatose | 2 | Shortening | 1.5 |
| Bitter Melon P.E | 1% | Arasaponin | 3% |
Fabrication processing figure refers to Figure of description 3.
Production method：
(1) weighing of raw material：Various raw materials are weighed by formula.
(2) prepare：With coolant-temperature gage, (summer is adjusted with ice water, and winter is adjusted with warm water, and winter flour indoor temperature exists for adjusting
Between 16-18 degree, it need to be adjusted with 40 degree or so warm water, summer flour temperature need to be carried out between 25-30 degree with 7-10 degree ice water
It adjusts)；A small amount of water (meter is among total water consumption) is poured into a small basin, salt and sugar is soluble in water, it is spare.
(3) powder is adjusted：It is put into flour in adjusting powder machine, then puts into active dry yeast, milk powder and Bitter Melon P.E, it is abundant with hand
Salt, sugar juice, water are added after mixing to be stirred.Low speed 3 divides, 5 points of high speed；Shortening and margarine (butter) is added,
Low speed 3 divides, 5-8 points of high speed.Dough taking-up is placed in the plastic box of coated oil, measuring temperature, dough temperature should be 26-28
DEG C, capping fermentation.
(4) it ferments：Fermentation temperature is 28-30 DEG C, and humidity 85%, fermentation presses powder after 1 hour 30, then is fermented 30 minutes points
It cuts.
(5) divide, rub garden and standing with the hands：Every piece of dough weight 250g, with hand rubbing garden and is placed in proofing box, is capped, room temperature
It is lower to stand 20 minutes.
(6) it is molded：Dough sheet is rolled into face stick, is rolled into the cylindrical mold for being placed in and coating oil in advance.
(7) molding fermentation：Molding product is put into fermenting case, is fermented.Temperature is 38 DEG C, humidity 90%, hair
Ferment 80-90 minutes.
(8) it toasts：Product through molding fermentation, is put into oven and toasts.Baking condition：It gets angry 160 DEG C, lower fiery 185 DEG C,
The rear adjusting of baking 15 minutes or so is got angry 195 DEG C, lower fiery 185 DEG C, then or baking observation in 25 minutes or so.
(9) cooling：Bread natural cooling at room temperature.
Above example is only used to illustrate the technical scheme of the present invention rather than its limitations, the ordinary skill people of fields
Member, which should be appreciated that, can be modified or replaced equivalently the specific implementation mode of the present invention with reference to above-described embodiment, these
Without departing from any modification of spirit and scope of the invention or equivalent replacement apply pending claims it
It is interior.
Claims (10)
1. a kind of composite formula, the composite formula includes following compositions：Inhibition sugar absorbing material, antioxidant,
Block the substance of diabetic complication access.
2. composite formula according to claim 1, wherein it is following that the inhibition sugar absorbing material, which can be selected from,
In any one or combinations thereof：Mulberry-leaf extract, propolis, L-arabinose and Tagatose.
3. composite formula according to claim 1, wherein：
(1) antioxidant, which also has, promotes insulin sensitivity effect；
(2) antioxidant can be selected from it is following any one or combinations thereof：Co-Q10, vitamin E, vitamin C, α-
Lipoic acid, Herba siegesbeckiae extracts, balsam pear extract, Astragalus Root P.E, Cortex cinnamomi japonici (Ramulus Cinnamomi) extract and iron sheet dry measure used in former times extract, the extraction of purple grape skin
Object and haw thorn extract.
4. composite formula according to claim 1, wherein the substance of the blocking diabetic complication access can be with
Selected from be it is following in any one or combinations thereof：Benfotiamine, vitamin B1, allithiamine, thiamine tetrahydrofuryl disfulfide, double isobutyl sulphur
Amine, lipoic acid, arasaponin, Radix Astragali, rheum officinale and propolis.
5. according to the composite formula described in claim 1-4, it includes：Mulberry-leaf extract, alpha-lipoic acid, benzene phosphorus sulphur ammonium.
6. composite formula according to claim 5, it includes：Mulberry-leaf extract 80-100mg, alpha-lipoic acid 100-
150mg, benzene phosphorus sulphur ammonium 40-60mg.
7. composite formula according to claim 6, it includes：Mulberry-leaf extract 100mg, alpha-lipoic acid 150mg, benzene phosphorus
Sulphur ammonium 50mg.
8. the composite formula of any one of claim 1-4 is preparing treatment or is preventing the medicine of diabetes and its related complication
Purposes in object, food or health products.
9. drug according to claim 8, pharmaceutical dosage form is chosen as capsule, tablet, pill, pill.
10. a kind of Pharmaceutical composition, it includes claim 1-4 formulas and pharmaceutically acceptable auxiliary materials, preferably pharmaceutic adjuvant
For linseed oil.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710280770.XA CN108785388A (en) | 2017-04-26 | 2017-04-26 | A kind of composite formula and preparation method treating and preventing diabetes and its complication |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710280770.XA CN108785388A (en) | 2017-04-26 | 2017-04-26 | A kind of composite formula and preparation method treating and preventing diabetes and its complication |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108785388A true CN108785388A (en) | 2018-11-13 |
Family
ID=64069103
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710280770.XA Pending CN108785388A (en) | 2017-04-26 | 2017-04-26 | A kind of composite formula and preparation method treating and preventing diabetes and its complication |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108785388A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101278977A (en) * | 2008-03-31 | 2008-10-08 | 中国科学院成都生物研究所 | Method for extracting main active components of mulberry leaf and application of its extract |
| CN104921099A (en) * | 2015-02-15 | 2015-09-23 | 武汉山楂树生物科技有限公司 | Diabetes specific complex oligopeptide food and manufacturing method and application thereof |
-
2017
- 2017-04-26 CN CN201710280770.XA patent/CN108785388A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101278977A (en) * | 2008-03-31 | 2008-10-08 | 中国科学院成都生物研究所 | Method for extracting main active components of mulberry leaf and application of its extract |
| CN104921099A (en) * | 2015-02-15 | 2015-09-23 | 武汉山楂树生物科技有限公司 | Diabetes specific complex oligopeptide food and manufacturing method and application thereof |
Non-Patent Citations (3)
| Title |
|---|
| V A,SERGIENKO等: "The effect of long-chain polyunsaturated higher ω-3 fatty acids, benfotiamine and α-lipoic acid on the lipid metabolism in patients with diabetes mellitus type 2 and cardiovascular autonomic neuropathy", 《ZHURNAL NEVROLOGII I PSIKHIATRII IMENI S.S. KORSAKOVA》 * |
| 余元勋等: "《中国分子糖尿病学》", 30 April 2016, 安徽科学技术出版社 * |
| 吕传真等: "《实用神经病学》", 31 January 2014, 上海科学技术出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101969062B1 (en) | Preparation Method of Gynostemma Pentaphyllum leaves Extract for Increasing small molecular effective Saponin contents, and Decreasing Benzopyrene, And Gynostemma Pentaphyllum Extract Using Thereof | |
| JP7010506B2 (en) | A method for producing a Jiaogulan leaf extract that increases the content of low-molecular-weight effective saponin and reduces the content of benzopyrene, and the Jiaogulan leaf extract obtained thereby. | |
| CN108143907A (en) | Health care tea formulation and its preparation method and application | |
| KR101102578B1 (en) | Method producing functional vinegar picked egg and functional vinegar picked egg produced by the same method | |
| AU2014292651A1 (en) | Anti-fatigue composition and use thereof | |
| US20180303889A1 (en) | Composition for prevention, alleviation, or treatment of peripheral neuropathy comprising lithospermi radix extract as an effective component | |
| CN115317574A (en) | Composition for treating hyperuricemia and application thereof | |
| CN107613998A (en) | Contain the prevention and treatment pharmaceutical composition or healthy food of the metabolic disease of Pleurotus ferulae water extract as active ingredient | |
| JP4205870B2 (en) | Lifestyle-related disease prevention / amelioration agent | |
| CN107106624A (en) | Prevention, the composition for the mixed extract containing mulberries and fuling peel for improving or treating degenerative neural disease | |
| CN108324705A (en) | Composition for relieving asthenopia containing theanine, γ-aminobutyric acid and anthocyanidin | |
| CN105212040A (en) | A kind of composite nutrition powder containing blank corn and preparation method thereof | |
| CN108785388A (en) | A kind of composite formula and preparation method treating and preventing diabetes and its complication | |
| CN107106620A (en) | Prevention, the composition for the bark extract containing Poria cocos for improving or treating degenerative neural disease | |
| KR101732483B1 (en) | Composition for prevention, improvement or treatment of peripheral neuropathy comprising Forsythiae Fructus extract as effective component | |
| KR20180052514A (en) | A method for manufacturing low temperature aging garlic and composition for antifatigue comprising there of extract | |
| RU2622337C1 (en) | Fatigue-relieving composition and its application | |
| CN109380728B (en) | Composition and health food with auxiliary blood pressure lowering effect | |
| CN108697753A (en) | Contain composition for prevent, improve or treat side effect by anticancer agent caused by disease of the Rhizoma Phragmitis extract as active ingredient | |
| CN106620090A (en) | Composition for reducing blood glucose, and preparation method of composition | |
| CN106819223A (en) | A kind of health-care milk tea and preparation method thereof | |
| CN108371326B (en) | Functional composition for reducing blood sugar | |
| KR100559493B1 (en) | Erectile dysfunction treating agent comprising Ogalpi extract | |
| KR20160056426A (en) | Composition for improving exercise performance and recovering fatigue comprising Gynura procumbens extract | |
| CN104721475B (en) | A kind of health care product used for relieving physical fatigue and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DD01 | Delivery of document by public notice |
Addressee: Aoweijia Biotechnology (Beijing) Co., Ltd. Document name: Notification to Make Rectification |
|
| DD01 | Delivery of document by public notice | ||
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20181113 |
|
| WD01 | Invention patent application deemed withdrawn after publication |